Obesity – Page 2

Lilly’s triple agonist retatrutide posts strongest weight-loss data to date, with unusual sensory skin side effect reported

1 month ago talkbio0Tagged Abnormal, aspects of adverse effects, Dysesthesia, Eli, Eli Lilly, Gastric Inhibitory Polypeptide, glucagon, Glucagon-Like Peptide 1, Obesity, Phase III, retatrutide, safety signal, sense of, Therapeutic tactile stimulation, triple agonist, triple hormone receptor agonist, TRIUMPH-4, Weight Loss

Eli Lilly; retatrutide; triple agonist; triple hormone receptor agonist; GLP-1; GIP; glucagon; obesity; weight loss; TRIUMPH-4; Phase III; dysesthesia; abnormal sense of touch; safety signal; side effects

Zealand Pharma and OTR Therapeutics in multi-program strategic collaboration for metabolic diseases

1 month ago talkbio0Tagged China, License Agreement, Metabolic Diseases, milestone payments, Obesity, oral small-molecule therapeutics, OXTR gene, Partnership, royalties, strategic collaboration, upfront payment, Zealand Pharma

Zealand Pharma; OTR Therapeutics; strategic collaboration; license agreement; metabolic diseases; obesity; oral small-molecule therapeutics; R&D partnership; China biotech; upfront payment; milestone payments; royalties

Wave Life Sciences RNA obesity shot shows fat loss with muscle preservation but trails Eli Lilly’s candidates

1 month ago talkbio0Tagged Adangme language, eli lilly, fat loss, INHBE, Injection of therapeutic agent, muscle preservation, Obesity, RNA obesity, Scientific Sessions, Wave Life Sciences, WVE-007

Wave Life Sciences; WVE-007; INHBE; RNA obesity drug; obesity shot; fat loss; muscle preservation; Eli Lilly; ADA Scientific Sessions

Biotech interest shifting from obesity ‘halo’ to other areas like oncology and blood cancers

1 month ago talkbio0Tagged Autoimmune, biotech pivot, Halo brace, Investments, leukemia, Neoplasms, Novartis, Obesity, sector rotation

obesity drugs; biotech pivot; investment trends; Novartis; leukemia; obesity halo; sector rotation; autoimmune; oncology

Structure Therapeutics’ oral obesity drug shows competitive early data vs Novo and Lilly; Ascletis reports early obesity results

1 month ago talkbio0Tagged ASC41, Ascletis, eli lilly, Glucagon-Like Peptide 1, GSBR-1290, Obesity, Oral cavity, Ozempic, Phase 2 trial, safety profile, Structure Therapeutics, Wegovy, Weight Loss, Weight-Loss Agents, Zepbound

Structure Therapeutics; GSBR-1290; oral GLP-1; obesity pill; weight-loss drug; Novo Nordisk; Eli Lilly; Wegovy; Ozempic; Zepbound; Ascletis; ASC41; ASC42; phase 1 trial; phase 2 trial; weight reduction; safety profile

Jesper Høiland Joins Alva Therapeutics’ Board of Directors

2 months ago talkbio0Tagged Alva Therapeutics, board of directors, Clinical Development, Diabetes Mellitus, Non-Insulin-Dependent, incretin secretagogue, Novo Nordisk, Obesity, Oral cavity, pharmaceutical commercialization

Alva Therapeutics; Board of Directors; Novo Nordisk; Type 2 diabetes; obesity; oral incretin secretagogue; clinical development; pharmaceutical commercialization

Jesper Høiland Joins Alva Therapeutics’ Board of Directors

2 months ago talkbio0Tagged Alva Therapeutics, board of directors, Clinical Development, Diabetes Mellitus, Non-Insulin-Dependent, incretin secretagogue, Novo Nordisk, Obesity, Oral cavity, pharmaceutical commercialization

Alva Therapeutics; Board of Directors; Novo Nordisk; Type 2 diabetes; obesity; oral incretin secretagogue; clinical development; pharmaceutical commercialization

Recent Developments on Vinay Prasad’s Leaked FDA Memo, Alzheimer’s Disease Updates, and Next-Gen Obesity Drugs

2 months ago talkbio0Tagged Alzheimer 's disease, Cessation of life, Child, COVID19 (disease), next-generation, Obesity, research, United States Food and Drug Administration, Vaccines, Vinay Prasad FDA memo

Vinay Prasad FDA memo; COVID-19 vaccine deaths children; FDA vaccine approval changes; Alzheimer’s disease research 2025; obesity drugs next generation; COVID-19 vaccine safety controversy; FDA vaccine policy overhaul

Recent obesity and IL-6 program updates for Fractyl, Helicore, and Tiziana

2 months ago talkbio0Tagged Autoimmune, Discontinuation (procedure), Fractyl Health, Glucagon-Like Peptide 1, Helicore, interleukin-6, Obesity, REVEAL-1, Revita, Tiziana Life Sciences, weight loss maintenance

Fractyl Health; Revita; REVEAL-1; weight loss maintenance; GLP-1 discontinuation; Helicore; Tiziana Life Sciences; IL-6; autoimmune; obesity

Researchers Advance Toward Matching Patients with the Most Effective GLP-1 Drug for Personalized Obesity Treatment

2 months ago talkbio0Tagged aspects of adverse effects, drug response, Genetic screening method, Glucagon-Like Peptide 1, Machine Learning, Mayo Clinic, MyPhenome, Obesity, personalized care, Precision Medicine, Prediction, Treatment Adherence

GLP-1; precision medicine; obesity; drug response prediction; genetic test; personalized care; side effects; machine learning; MyPhenome; Mayo Clinic; treatment adherence